Cargando…

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

BACKGROUND: This retrospective observational study validated nuclear grading criteria developed to identify a high-risk group with recurrence rate ≥20–30% and local pathology diagnosis used in a previous multi-institutional randomized N·SAS-BC 01 trial, where the efficacy of adjuvant chemotherapy re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuda, Hitoshi, Kurosumi, Masafumi, Akiyama, Futoshi, Ohno, Shinji, Saji, Shigehira, Masuda, Norikazu, Shimomura, Akihiko, Sato, Nobuaki, Takao, Shintaro, Ohsumi, Shozo, Tokuda, Yutaka, Inaji, Hideo, Watanabe, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225977/
https://www.ncbi.nlm.nih.gov/pubmed/35435571
http://dx.doi.org/10.1007/s12282-022-01350-4
_version_ 1784733743392489472
author Tsuda, Hitoshi
Kurosumi, Masafumi
Akiyama, Futoshi
Ohno, Shinji
Saji, Shigehira
Masuda, Norikazu
Shimomura, Akihiko
Sato, Nobuaki
Takao, Shintaro
Ohsumi, Shozo
Tokuda, Yutaka
Inaji, Hideo
Watanabe, Toru
author_facet Tsuda, Hitoshi
Kurosumi, Masafumi
Akiyama, Futoshi
Ohno, Shinji
Saji, Shigehira
Masuda, Norikazu
Shimomura, Akihiko
Sato, Nobuaki
Takao, Shintaro
Ohsumi, Shozo
Tokuda, Yutaka
Inaji, Hideo
Watanabe, Toru
author_sort Tsuda, Hitoshi
collection PubMed
description BACKGROUND: This retrospective observational study validated nuclear grading criteria developed to identify a high-risk group with recurrence rate ≥20–30% and local pathology diagnosis used in a previous multi-institutional randomized N·SAS-BC 01 trial, where the efficacy of adjuvant chemotherapy regimens was evaluated in 733 high-risk node-negative invasive breast cancer patients. METHODS: Of 545 patients with long-term follow-up data (median 12.1 years), pathology slides, and local pathology diagnosis, 530 eligible patients were subjected to central pathology review (CPR) for histological type and nuclear grade (NG). Concordance in NGs was compared with local diagnosis. The 10/15-year recurrence-free survival (RFS) and overall survival (OS) rates stratified by NG and histological type were calculated. RESULTS: Local diagnoses were invasive ductal carcinoma (IDC)-NG2, IDC-NG3, invasive lobular carcinoma (ILC), and metaplastic carcinoma (MC) in 158/327/38/7 patients, respectively. The 10/15-year RFS rates were 87.2/82.6% for IDC-NG2 and 81.8/75.0% for IDC-NG3 (p = 0.061), and OS rates were 95.0/92.8% for IDC-NG2 and 90.8/85.7% for IDC-NG3 (p = 0.042). CPR graded 485 locally diagnosed IDCs as IDC-NG1/NG2/NG3/unknown in 98/116/267/4 patients, respectively. No significant difference was found among survival curves for the three NG groups. Although the agreement level between local and CPR diagnoses was low (κ = 0.311), both diagnoses identified a patient group with a 15-year recurrence rate ≥ 20%. The 10/15-year RFS rates were 79.4/63.5% for ILC and 68.6%/unknown for MC. CONCLUSIONS: The N·SAS grading system identified a patient group with high-risk node-negative invasive breast cancer, suggesting that local diagnosis was performed efficiently in the N·SAS-BC 01 trial. Trial registration number: UMIN000022571. Date of registration: June 1, 2016. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12282-022-01350-4.
format Online
Article
Text
id pubmed-9225977
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-92259772022-06-25 Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial Tsuda, Hitoshi Kurosumi, Masafumi Akiyama, Futoshi Ohno, Shinji Saji, Shigehira Masuda, Norikazu Shimomura, Akihiko Sato, Nobuaki Takao, Shintaro Ohsumi, Shozo Tokuda, Yutaka Inaji, Hideo Watanabe, Toru Breast Cancer Original Article BACKGROUND: This retrospective observational study validated nuclear grading criteria developed to identify a high-risk group with recurrence rate ≥20–30% and local pathology diagnosis used in a previous multi-institutional randomized N·SAS-BC 01 trial, where the efficacy of adjuvant chemotherapy regimens was evaluated in 733 high-risk node-negative invasive breast cancer patients. METHODS: Of 545 patients with long-term follow-up data (median 12.1 years), pathology slides, and local pathology diagnosis, 530 eligible patients were subjected to central pathology review (CPR) for histological type and nuclear grade (NG). Concordance in NGs was compared with local diagnosis. The 10/15-year recurrence-free survival (RFS) and overall survival (OS) rates stratified by NG and histological type were calculated. RESULTS: Local diagnoses were invasive ductal carcinoma (IDC)-NG2, IDC-NG3, invasive lobular carcinoma (ILC), and metaplastic carcinoma (MC) in 158/327/38/7 patients, respectively. The 10/15-year RFS rates were 87.2/82.6% for IDC-NG2 and 81.8/75.0% for IDC-NG3 (p = 0.061), and OS rates were 95.0/92.8% for IDC-NG2 and 90.8/85.7% for IDC-NG3 (p = 0.042). CPR graded 485 locally diagnosed IDCs as IDC-NG1/NG2/NG3/unknown in 98/116/267/4 patients, respectively. No significant difference was found among survival curves for the three NG groups. Although the agreement level between local and CPR diagnoses was low (κ = 0.311), both diagnoses identified a patient group with a 15-year recurrence rate ≥ 20%. The 10/15-year RFS rates were 79.4/63.5% for ILC and 68.6%/unknown for MC. CONCLUSIONS: The N·SAS grading system identified a patient group with high-risk node-negative invasive breast cancer, suggesting that local diagnosis was performed efficiently in the N·SAS-BC 01 trial. Trial registration number: UMIN000022571. Date of registration: June 1, 2016. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12282-022-01350-4. Springer Nature Singapore 2022-04-18 2022 /pmc/articles/PMC9225977/ /pubmed/35435571 http://dx.doi.org/10.1007/s12282-022-01350-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Tsuda, Hitoshi
Kurosumi, Masafumi
Akiyama, Futoshi
Ohno, Shinji
Saji, Shigehira
Masuda, Norikazu
Shimomura, Akihiko
Sato, Nobuaki
Takao, Shintaro
Ohsumi, Shozo
Tokuda, Yutaka
Inaji, Hideo
Watanabe, Toru
Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
title Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
title_full Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
title_fullStr Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
title_full_unstemmed Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
title_short Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
title_sort validation of a nuclear grading system for resected stage i–iiia, high-risk, node-negative invasive breast carcinoma in the n·sas-bc 01 trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225977/
https://www.ncbi.nlm.nih.gov/pubmed/35435571
http://dx.doi.org/10.1007/s12282-022-01350-4
work_keys_str_mv AT tsudahitoshi validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT kurosumimasafumi validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT akiyamafutoshi validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT ohnoshinji validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT sajishigehira validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT masudanorikazu validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT shimomuraakihiko validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT satonobuaki validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT takaoshintaro validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT ohsumishozo validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT tokudayutaka validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT inajihideo validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial
AT watanabetoru validationofanucleargradingsystemforresectedstageiiiiahighrisknodenegativeinvasivebreastcarcinomainthensasbc01trial